Here is a synopsis of why USNA and CPTS have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:
USANA Health Sciences, Inc.? (USNA
) fourth-quarter earnings of 75 cents per share, reported on
Feb 9, missed the Zacks Consensus Estimate by nearly 10%. The
last month has seen downward revisions by all the 5 covering
analysts, pulling the full-year average forecast down by 43
cents to $2.92 per share. Moreover, the following year?s
estimate fell 20 cents to $3.45 per share during that time.
Conceptus, Inc. (CPTS
) announced fourth-quarter earnings of 14 cents per share on
Feb 24, which was 4 cents short of the Zacks Consensus
Estimate. Gross profit margin was 81.9% of net sales for the
fourth quarter of 2010, compared with 82.2% for the fourth
quarter of 2009. The year-over-year decrease in gross profit
margin was primarily the result of lower international
average selling prices due to foreign currency. The
full-year average forecast slid 13 cents to 14 cents per
share in the last 30 days as 6 analysts out of 10 cut
estimates.
TPC Group, Inc. (TPCG
) posted a second-quarter profit of 7 cents per share on
March 3 that was 70% behind the average forecast. The Zacks
Consensus Estimate for 2011 decreased 36 cents to $1.97 per
share over the past week as the only covering analyst cut
back on projections.
CStepan Company (SCL)
On Feb 8, the company reported earnings per share of $1.02,
which fell 12% short of the Zacks Consensus Estimate. For the
current year, the average forecast moved down 16 cents to a
profit of $6.51 per share in the last 30 days as the only
covering analyst lowered expectations.
CONCEPTUS INC (CPTS): Free Stock Analysis Report
STEPAN CO (SCL): Free Stock Analysis Report
USANA HLTH SCI (USNA): Free Stock Analysis Report
Zacks Investment Research
Here is a synopsis of why TPCG and SCL have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.